SELECTED IMPORTANT SAFETY INFORMATION: KOVALTRY® is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins. CONTINUE READING BELOW >

SELECTED IMPORTANT SAFETY INFORMATION: KOVALTRY®

is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

CONTINUE READING BELOW

Explore the coverage of KOVALTRY®

Cross-over study examining PK characteristics of KOVALTRY® and Advate® (N=18)

Explore the coverage of KOVALTRY®

Cross-over study examining PK characteristics of KOVALTRY® and Advate® (N=18)1

PK parameters of KOVALTRY® in the LEOPOLD I trial (arithmetic mean ± SD)3

PK parameters were measured using chromogenic substrate assay after a single 50 IU/kg dose of KOVALTRY® in 21 previously treated patients ≥18 years old

Parameter (unit)
≥18 years
AUC (IUh/dL)
2103.4 ± 702.8
Cmax (IU/dL)
133.1 ± 20.4
t1/2 (h)
14.2 ± 3.5
MRTIV (h)
19.9 ± 4.9
VSS (dL/kg)
0.50 ± 0.11
CL (dL/h/kg)
0.027 ± 0.010

AUC=area under the curve

CL=clearance

Cmax=maximum concentration

LEOPOLD=Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease

MRTIV=mean residence time after intravenous administration

PK=pharmacokinetics

SD=standard deviation

t1/2=half-life

Vss=apparent volume of distribution at steady state

Study summary1,2
Study description The PK profiles of KOVALTRY® and Advate® were compared in a single-dose, open-label, randomized, cross-over study Previously treated male patients aged 18 to 65 years (N=18) with severe hemophilia A
Dosing Patients were randomized to a single infusion of KOVALTRY® (50 IU/kg) (n=9) or Advate® (50 IU/kg) (n=9)

Patients were then crossed over to a single infusion of the other treatment, with time for washout

Patients experienced a greater than or equal to three-day washout period before receiving a single infusion of the other treatment.
PK assessment Plasma samples were collected predose and at 0.25, 0.5, 1, 3, 6, 8, 24, 30, and 48 hours postdose for PK assessment

PK=pharmacokinetics.

Dosing and PK parameters of KOVALTRY® in a study of adults3:
The recommended dosing of KOVALTRY® for routine prophylaxis is 20–40 IU/kg 2x/week or 3x/week in adults. In a study of KOVALTRY®, PK parameters were measured after a single 50-IU/kg dose of KOVALTRY® in 21 previously treated patients ≥18 years old. The average area under the curve was 2103.4 IU•h/dL. The average maximum concentration was 133.1 IU/dL. The average half-life was 14.2 hours.

PK parameters were measured using chromogenic substrate assay after a single 50 IU/kg dose of KOVALTRY® in 21 previously treated patients ≥18 years old

See the PK results of KOVALTRY® and Advate® from the cross-over PK study

INDICATION FOR KOVALTRY®

KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

KOVALTRY is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY if symptoms occur and seek immediate emergency treatment.

KOVALTRY may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation has occurred following administration of KOVALTRY. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and pyrexia, headache, and rash.

For additional important risk and use information, please see full Prescribing Information.

 

References: 1. Shah A, Solms A, Garmann D, et al. Improved pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A [published online December 22, 2016]. Clin Pharmacokinet. doi:10.1007/s40262-016-0492-2. 2. Data on file. Bayer HealthCare Pharmaceuticals, Inc; 2016. 3. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2021.